9.34

5.66% -0.56

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $9.34, with a volume of 890.79K. It is down -5.66% in the last 24 hours and up +11.72% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Previous Close:

$9.90

Open:

$9.91

24h Volume:

890.79K

Relative Volume:

0.64

Market Cap:

$565.91M

Revenue:

$217.11M

Net Income/Loss:

$-651.19M

P/E Ratio:

-0.719

EPS:

-12.99

Net Cash Flow:

$-387.26M

1W Performance:

+0.97%

1M Performance:

+11.72%

6M Performance:

+0.54%

1Y Performance:

-9.58%

1-Day Range:

$9.32

$10.08

1-Week Range:

$9.22

$10.08

52-Week Range:

$5.00

$17.58

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

834

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	9.34	599.84M	217.11M	-651.19M	-387.26M	-12.99
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Dec 11, 2025

Is Ginkgo Bioworks Holdings Inc a good long term investmentSector-Based Investing & Rapid Capital Appreciation - earlytimes.in

Dec 11, 2025

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies - Investing News Network

Dec 11, 2025

Jump Financial LLC Acquires New Stake in Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat

Dec 11, 2025

Dec 10, 2025

Recent Uptick Might Appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Institutional Owners After Losing 13% Over the Past Year - 富途牛牛

Dec 10, 2025

Dec 09, 2025

Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform - marketscreener.com

Dec 09, 2025

Ginkgo Bioworks Partners on Deep Origin-Led Team to Develop New Tools for Pred Predictive Drug Safety - marketscreener.com

Dec 09, 2025

Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety - Finviz

Dec 09, 2025

Ginkgo Bioworks partners with Deep Origin on ARPA-H drug safety project - Investing.com UK

Dec 09, 2025

Ginkgo Bioworks (NYSE: DNA) to aid ARPA-H CATALYST drug safety modeling platform - Stock Titan

Dec 09, 2025

Dec 06, 2025

Ginkgo Bioworks (NYSE:DNA) Shares Gap UpWhat's Next? - MarketBeat

Dec 06, 2025

Ginkgo Bioworks to Hold Special Meeting of Shareholders - GuruFocus

Dec 06, 2025

Dec 05, 2025

Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform - Investing.com

Dec 05, 2025

Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform By Investing.com - Investing.com South Africa

Dec 05, 2025

Ginkgo Bioworks Awarded 4-Year Energy Department Contract Valued at Up to $47 Million - marketscreener.com

Dec 05, 2025

Ginkgo Bioworks stock rises on $47M DOE contract award By Investing.com - Investing.com South Africa

Dec 05, 2025

Ginkgo Bioworks stock rises on $47M DOE contract award - Investing.com India

Dec 05, 2025

Ginkgo Bioworks Holdings Inc selected by PNNL to deliver a modular, high-throughput phenotyping platform for DOE's M2PC - marketscreener.com

Dec 05, 2025

Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High-Throughput Phenotyping Platform for DOE's M2PC - Finviz

Dec 05, 2025

Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC - marketscreener.com

Dec 05, 2025

Dec 04, 2025

Will Ginkgo Bioworks Holdings Inc. Class stock announce a stock splitCEO Change & AI Based Buy and Sell Signals - Newser

Dec 04, 2025

Is Ginkgo Bioworks Holdings Inc. stock a buy before product launchesMarket Rally & Consistent Growth Equity Picks - Newser

Dec 04, 2025